Crossject : 2019 annual results and business update

Press release

2019 annual results and business update

• Operational facilities resolutely preparing for large series
• Gradual focus on the United States
• Reduction of losses, thanks in large part to commercial activities
• Covid-19likely to have an impact on timing, but teams remain operational

Dijon, 26 March 2020

CROSSJECT (ISIN: FR0011716265; Ticker: ALCJ), a specialty pharma company that is developing and will soon be marketing a portfolio of combined drugs for use in emergency situations, is announcing its 2019 results and issuing a business update.

Patrick Alexandre, CEO of Crossject, said: "2019 was a bumper year for the company. The contract signed with Desitin Pharma and the R&D cooperation agreement with the United States Department of Defense demonstrate the value of our products and our technology, and that is something we are proud of. Today, our industrial facilities are able to produce ZENEO®devices, from components to the finished product. In the coming year, we will continue our efforts to prepare our supply chain for a ramp-up of production, while remaining vigilant about its robustness and regulatory compliance at every stage of the process. We are also counting on the conclusion of new commercial agreements given the quality of our products, which we continue to improve, such as ZENEO® Adrenaline and its new medicinal formulation. The progress made in 2019 is the result of the combined efforts of all our teams and the support of our shareholders. I thank them all. In the context marked by the Covid-19 epidemic, our priority is to protect our employees and preserve our operational achievements. At the moment, it is still too early to measure the impact the epidemic will have on our business, but we all remain committed to our shared ambition: make Crossject the leader in emergency drugs."

Update on activity since the start of 2020

Industrial advances: operational facilities resolutely preparing for large series

In 2019, Crossject continued its efforts to improve and secure its industrial facilities ready for large-scale production. An inspection of our manufacturer by the Belgian authorities during the production of a batch of ZENEO® Naloxone served to confirm that all production lines are approved for the manufacture

1

of the clinical batches necessary for MA1 dossiers. Crossject also continued its capex policy in 2019: its automated tube washing by integrating it into the PARC® production module, and implemented an integrated management software package (ERP) to streamline the supply chain. Moreover, the company has improved quality procedures applying both to suppliers and internally at all stages of production. It has also invested in securing its supply for the most critical components (double sourcing and duplication of certain production facilities) and pharmaceutical raw materials (multi-year inventory policy).

Crossject is also on track for ISO 13485 certification. The results of the mock audit carried out in 2019 and the receipt of pharmaceutical establishment status demonstrate the pertinence of Crossject's quality approach.

Continued development of the drug portfolio

Crossject is actively pursuing the development of its drug portfolio with a view to filing its first MA dossiers.

In 2019, a "human factors" study was carried out in America, giving very good results. 146 volunteers placed in the conditions of a life-threatening emergency tested ZENEO® Midazolam, ZENEO® Adrenaline, ZENEO® Terbutaline and ZENEO® Naloxone. 87% successfully completed all stages until injection. Of the 99 volunteers questioned following their use of ZENEO®, 94% agreed that the system's general use did not pose problems for them, with 36% describing it as "easy" and 45% as "very easy".

The industrial transfer(adaptation and qualification of production methods defined in the laboratory on industrial lines) for ZENEO® Naloxone and ZENEO® Midazolam has been the subject of intense activity, involving close work with our manufacturing partner. The stability data of the batches produced (in particular the 12-month data concerning Midazolam), are in line with our expectations.

ZENEO® Midazolam: significant advances in 2019

In 2019, ZENEO® Midazolam chalked up significant advances confirming the drug's appeal and potential.

First, Crossject signed a commercial agreement on ZENEO® Midazolam in Germany with Desitin Pharma, leader in the field of epilepsy in Germany. The agreement concerns licensing, distribution and promotion for a period of 10 years from commercial launch, unless either Crossject or Desitin opts to exercise certain withdrawal clauses, for instance if minimum sales are not reached or if certain milestones are not respected. Desitin paid Crossject €0.5 million on signing. It will pay €0.5 million on a development milestone expected in 2020, then €0.5 million on an additional development milestone expected within 12 months, plus a further €1 million when the MA is obtained. Crossject will sell the product to Desitin at a percentage of the net selling price applied by Desitin to wholesalers, in the mid-double digits and with

1 Marketing authorisation

2

a floor unit price.

Second, the company has signed a research and development cooperation agreement with the United States Department of Defense (DoD). Benzodiazepine auto-injection systems are currently the gold- standard treatment for victims of attack with a nerve agent.

The interest shown by several federal agencies is a real opportunity to reposition ZENEO® Midazolam in America, despite the "orphan drug" exclusivity previously granted in the indication of Status Epilepticus to another injectable midazolam product presented in an ampoule for injection with a needle. To that end, Crossject consulted the FDA2 about ZENEO® Midazolam at the end of the year.

ZENEO® Adrenaline: enhanced commercial potential

On 20 March 2020, Crossject announced two major advances for ZENEO® Adrenaline.

As recently explained,3 the 2019 patent application for a new formulation of ZENEO® Adrenaline, an emergency treatment against anaphylactic shock (allergic reaction), was the subject of a favourable report by the INPI4 on all patentability criteria. On one hand it does not contain sulphites, the drug solution is not allergenic; at the same time, its shelf life should be longer than that of the products currently on the market. On top of that, the volume of active ingredient remaining in the device after use is minute in comparison with other self-injection systems.

Crossject has also announced that it has repurchased the marketing and development rights for ZENEO® Adrenaline. The transaction holds out the prospect of the signing of new licensing agreements with higher upfront payments, thanks to the new formulation and the maturity of the development of the ZENEO® platform.

ZENEO® Naloxone: a promising market, currently on hold

In 2019, Crossject had discussions with the FDA on the development of ZENEO® Naloxone. Faced with the mounting number of deaths from the use of opioid painkillers, the United States is seeking emergency treatment for overdoses. ZENEO® Naloxone responds perfectly to emergency situations like those.

However, given recent news concerning large laboratories accused of having inappropriately promoted opioid-based painkillers, and which could be forced to distribute Naloxone rescue kits at their expense, Crossject is taking the time to analyse the situation and opportunities in the light of ongoing developments.

ZENEO® Methotrexate: recovery of commercial rights for France

1. Food and Drug Administration
2. See press release dated 20 March 2020
3. French National Industrial Property Institute (Institut National de la Propriété Industrielle)

3

By mutual agreement, the partnership signed in July 2012 between Crossject and Biodim for ZENEO® Methotrexate has been terminated in France. Biodim has been acquired by Neuraxpharm, a laboratory specialising in neurology, and which has no marketing activity in the segment of rheumatoid arthritis, the condition treated by ZENEO® Methotrexate. The amicable termination does not entail the reimbursement by Crossject of the €250,000 paid by Biodim when the contract was signed. Crossject once again holds the rights to ZENEO® Methotrexate in France.

Business development: continuation of commercial efforts

In 2019, Crossject continued its business development efforts, which resulted in the conclusion of the commercial agreement with Desitin Pharma on ZENEO® Midazolam in Germany and the cooperation agreement with the DoD. The team is fully committed to continuing its efforts based on the good newsflow on ZENEO® Adrenaline and the prospects for ZENEO® Midazolam (see above).

In addition, the Crossject Supervisory Board has authorised the Management Board to create a legal entity in the United States in order to be able to employ personnel there, notably in business development.

Covid-19 information and outlook

Crossject is making every effort to ensure the safety of its employees and limit the impact of the epidemic on its activity.

From the start of the epidemic, measures were taken to protect employees whose activity requires their physical presence on the Gray and Dijon production sites. Telework has been adopted for all activities that allow it, with most employees having the means necessary to continue their activities thanks to our anticipations upstream.

Given the magnitude and uncertain duration of the Covid-19 epidemic, it is too early to accurately assess its impact on Crossject's business. However, the suspension of certain activities will have consequences on the timing of submission of the first MA dossiers. The production of the first two clinical batches, well advanced before the government lockdown measures, has had to be suspended. It will not resume until they have been lifted. Crossject has already decided to prioritise the development of ZENEO® Midazolam under the agreement with Desitin and the pursuit of discussions with the American federal authorities interested in the product, in order to cement progress. To date, bi-weekly updates with the DoD have not been disturbed by the unfolding epidemic.

Crossject will continue development work on its other priority products, reserving the possibility of reviewing the prioritisation of its portfolio based on commercial progress.

4

Note that there is no risk of supply disruption for our customers, since Crossject's products are still in the development phase.

Crossject's cash position increased to €7.9 million at the end of 2019. The company has taken measures to limit its expenses and postpone non-priority spending. It is also studying all of the various possibilities announced recently by the government to address the crisis.

Financial information as of 31 December 2019

	€ thousand, as of 31 December	2019	2018
	Operating income	5,994	3,524
	Operating expenses	(14,637)	(15,081)
	Other purchases and external expenses	(6,391)	(7,659)
	Personnel expenses	(4,307)	(3,972)
	Taxes and duties	(142)	(126)
	Depreciation, amortisation and provisions	(3,797)	(3,324)
	Operating profit/(loss)	(8,643)	(11,557)
	Financial income/(expense)	110	(737)
	Exceptional income/(expense)	22	(10)
	Income tax	1,336	1,592
	Net profit/(loss)	(7,174)	(10,712)

The financial statements for the year ended 31 December 2019 were approved by the Management Board at its meeting of 24 March 2020 and presented at the Supervisory Board meeting of 24 March 2020. The auditors' report is pending.

Operating income totalled €6.0 million in 2019, an increase of €2.5 million. Crossject generated revenue of €0.5 million during the year, with the first upfront provided for by the marketing agreement with Desitin. Capitalised production rose from €2.4 million at the end of 2018 to €3.9 million at the end of 2019. Crossject also recognised €1 million in connection with the renegotiation of the ZENEO® Adrenaline contract (see press release dated 20 March 2020).

Operating expenses were stable at €14.6 million, compared with €15.1 million in 2018, reflecting the company's good control of expenses in a context of development and continued hiring. As of 31 December 2019, the company had 77 employees, compared with 75 at the end of 2018.

2019 operating income was a negative €8.6 million (negative €11.6 million in 2018). The net loss totalled €7.1 million (loss of €10.7 million in 2018).

As of 31 December 2019, Crossject had a higher amount of cash and cash equivalents of €7.9 million, compared with €4.8 million at the end of 2018. As a reminder, Crossject supplemented its funding with various cash contributions in 2019:

• upfront payment of €0.5 million,

5

• structured financing of €2.6 million,
• proceeds of €3.2 million from the exercise of warrants,
• public funding, with €1.9 million received in the second half (CIR, PIAVE, DGA, Europe, VAT, etc.),
• issue of €5.7 million in convertible bonds.

Crossject anticipates additional cash flows in 2020 in the form of aid under contract and commercial income from existing or new licensing agreements. These amounts will enable the company to fund its priority developments in 2019. In addition, Crossject is continuing its efforts to strengthen its long-term financing.

Contacts:

Crossject	Investor relations
Patrick Alexandre	CIC Market Solutions
[e-mail]	Catherine Couanau [phone]
	[e-mail]

Press relations

Buzz & Compagnie

Mélanie Voisard [phone] [e-mail] Distinguin [phone] [e-mail]

About CROSSJECT • www.crossject.com

Crossject (ISIN: FR0011716265; Ticker: ALCJ; LEI: 969500W1VTFNL2D85A65) is developing and is soon to market a portfolio of drugs

dedicated to emergency situations: epilepsy, overdose, allergic shock, severe migraine and asthma attack. Thanks to its patented needle- free self-injection system, Crossject aims to become the world leader in self-administered emergency drugs. The company has been listed on the Euronext Growth market in Paris since 2014, and benefits from Bpifrance funding.

6

Appendix: Financial statements for the six months to 31 December 2019

	Income statement (in €k)	Dec-19	Dec-18	Change
	Revenue	507				507
	Stored production	23		645		-622
	Capitalised production	3921		2423		1,498
	Operating subsidies	481		21		460
	Reversals of depreciation, amortisation	61		435		-374
	and provisions, transfer of expenses
	Other income	1,000				1,000
	Total operating income	5,993		3,524		2,469
	Inventories of purchases					0
	Other purchases and external expenses	6,391		7,658		-1,267
	Taxes, duties and similar payments	142		126		16
	Wages and salaries	2,973		2,729		244
	Social security contributions	1,334		1,244		90
	Depreciation and amortisation of fixed	3,647		2,968		679
	assets
	Provisions	149		355		-206
	Other expenses					0
	Total operating expenses	14,636		15,080		-444
	OPERATING PROFIT/(LOSS)	-8,643		-11,556		2,913
	FINANCIAL INCOME/(EXPENSE)	110		-737		847
	RECURRING INCOME BEFORE TAX	-8,533		-12,293		3,760
	EXCEPTIONAL INCOME/(EXPENSE)	23		-10		33
	Income taxes	1,336		1,592		-256
	NET PROFIT/(LOSS)	-7,174		-10,711		3,537

7

	Balance sheet - Assets (in €k)		31-Dec-19					Dec-		Change
	Gross			Depreciation		Net
					18
	Fixed assets
	Research and	16,031		9,810		6,221		4,615		1,606
	development
	Concessions, patents,	20,429		20,429		0		0		0
	similar rights
	Other intangible assets	185		152		33		36		-3
	Land	75					75		75		0
	Buildings	3,699		547		3,152		3,326		-174
	Industrial plant, machinery	6,378		4,211		2,167		2,577		-410
	and equipment
	Other property, plant and	789		406		383		363		20
	equipment
	Assets under construction
	Other equity investments	100					100		100		0
	Other long-term	1,562		1,217		345		180		165
	investments
	Other financial assets	46					46		55		-9
	Sub-total	49,294			36,772			12,522			11,327			1,195
	Current assets
	Inventories	1,870		416		1,454		1,523		-69
	Advances and									159		-159
	prepayments on orders
	Trade and other	5					5					5
	receivables
	Other receivables	2,085					2,085		1,826		259
	Investment securities	103					103		59		44
	Available cash	7,802					7,802		4,760		3,042
	Prepaid expenses	324					324		225		99
	Sub-total	12,189			416			11,773			8,552			3,221
	Deferred expenses	200					200		280		-80
	Total	61,683			37,188			24,495			20,159			4,336

8

	Balance sheet - Liabilities (in €k)	Jan-19	Dec-18	Change
	Shareholders' equity
	Share capital	2,020		13,603		-11,583
	Share, merger, contribution premiums, etc.	1,880		1,895		-15
	Regulated reserves	6,288				6,288
	Retained earnings			-3,132		3,132
	Profit/(loss) for the year	-7,174		-10,711		3,537
	Sub-total	3,014		1,655		1,359
	Conditional advances	5,195		5,195		0
	Provisions for contingencies and
	charges
	Provisions for contingencies
	Provisions for charges	182		125		57
	Sub-total	182		125		57
	Borrowings and debt
	Bonds	5,799		5,475		324
	Bank loans and debts	2,100		1,000		1,100
	Loans and various borrowings	543				543
	Advances and down-payments received on	2,600		1,000		1,600
	orders in progress
	Trade and other payables	1,915		2,568		-653
	Tax and social security payments	629		526		103
	Debts on fixed assets	2,514		2,614		-100
	Other liabilities	4		1		3
	Sub-total	16,104		13,184		2,920
	Total	24,495		20,159		4,336

9